Malissa Wood, MD, co-director of Corrigan Women’s Heart Health Program at Massachusetts General Hospital, shares some of the latest data from the iSCAD Registry.

While cardiac damage reverses in many patients following treatment, it can actually continue to get worse in others. 

Cardiologists and other physicians have always believed cardiac transthyretin amyloidosis, a progressive heart condition associated with a high mortality rate, was irreversible. Now, though, new evidence suggests that there may be hope. 

Jonathan Lindner, MD, offers an update on the use of echocardiography and bubble contrast agents in a therapy role to help revascularize STEMI patients and increase drug and gene delivery.

The new AUC document, which examines the treatment of both symptomatic and asymptomatic patients, was published in full in the Journal of the American College of Cardiology.

Cedars-Sinai researchers are developing a deep-learning algorithm to personalize patient cardiac risk predictions in a patient-friendly, graphical report.

The new analysis, published in JAMA, suggests that CT results can help identify medium- and high-risk patients who may need to be considered for statin therapy or other preventive treatments.